NCT05996224尚未招募3 期
A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) Therapy for Knee Osteoarthritis.
Shanghai AbelZeta Ltd.6 个研究点 分布在 1 个国家目标入组 488 人开始时间: 2023年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 488
- 试验地点
- 6
- 主要终点
- WOMAC score
研究概览
简要总结
Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy
详细描述
A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) Therapy for Knee Osteoarthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who understand and voluntarily sign the consent form before this study；
- •According to the diagnostic criteria (American Rheumatology Association, clinical + radiology criteria), patients with knee osteoarthritis are definitely diagnosed；
- •Age: 40-75, males and females；
- •The course of knee osteoarthritis was more than 6 months;
- •The subjects' WOMAC score was 24-72, and the WOMAC pain score was 7-17 (the WOMAC score at least 48 hours after discontinuation of all painkillers);
- •The Kellgren Lawrence grade (X-ray axial position of knee joint) of subjects was grade II / III;
- •Subjects are generally in good condition and can walk autonomously, except for those who use wheelchairs, walking aids or crutches.
排除标准
- •The subject may be allergic to the main cell preparation components (B vitamins, amino acids and so on).
- •The subject received systemic and / or local treatment with autologous and / or allogeneic mesenchymal progenitor cells.
- •The subject has a BMI of over
- •Laboratory test (any item meets): neutrophil absolute number < 1.0 × 10^9 / L, platelet count < 50 × 10^9 / L, serum albumin < 30g / L, serum creatinine > upper limit of 1.2 times normal value range, total bilirubin、alanine aminotransferase、aspartate aminotransferase > upper limit of 2 times of normal value range.
- •The subject has diseases or symptoms may affect VAS, WOMAC and so on.
- •The subject has serious and poorly controlled concomitant diseases, such as (but not limited to) nervous system, cardiovascular, liver, kidney, gastrointestinal and endocrine diseases, which may prevent the subjects from participating in the study according to the judgment of the researchers.
- •The subject has an history malignant tumour.
- •The subject has connective tissue disease or rheumatoid arthritis、chondropathy、Chondrocalcinosis articularis、 Hemochromatosis、inflammatory arthropathy、avascular necrosis of femoral head、Paget's disease、hemophilic arthropathy、infectional arthritis、Charcot' s disease、villonodular synovitis or synovial chondromatosis.
- •The subject has severe generalized infectious diseases or local knee infection (including skin and intra-articular infection) in the 3 months prior to this trial.
- •According to the researchers, the subject has disease of lower limbs which may be interfered knee evaluation, for example fibromyalgia, osphyalgia, lumbar disc protrusion and so on.
- •The subject had any other coagulation dysfunction caused by acute or chronic diseases, according to the judgment of the researchers, this coagulation dysfunction may endanger the safety of patients and / or affect the judgment of knee joint evaluation indicators.
- •The subject has received arthroscopic surgery or other open surgery related to knee joint operation in the 6 months prior to this trial.
- •The subject has received other intra-articular injections, including but not limited to hyaluronic acid, hormone, PRP, BMP (bone morphogenetic protein) , hypertonic glucose and so on for KOA in the 3 months preceding the trial.
- •The subject has received aminoglucose or chondroitin sulfate within 1 month before the treatment.
- •The subject has used dexamethasone, prednisone, hydrocortisone and other hormones orally / intravenously within 1 month before the treatment.
- •The subject has attenuated or live attenuated vaccine injection with 1 month before the treatment.
- •The subject has undergone knee prosthesis or a plan of knee prosthesis within the trial.
- •The subject has contraindication of MRI, included but not only: the subject installed heart pacemaker, defibrillator, heart bracket, heart valve prosthesis, metal clip after aneurysm surgery, drug infusion device implanted in vivo, any electronic device implanted in the body (nerve stimulator, bone growth stimulator) endovascular coil, strainer, ECG monitor, metal suture, shrapnel or sand of body, plate fixation and steel nail after fracture surgery, artificial cochlea, middle ear shift plant, metallic intraocular foreign body etc; the subject is a claustrophobia, critical ill patient and so on.
- •The subject tests positive for: HIV, HBV, HCV and treponema pallidum.
- •The subject has history of alcoholism, drug abuse, or mental illness in the 3 years prior to this trial.
- •The subject has participated in any other clinical trial in the 3 months prior to this trial.
- •The subject (including male subjects) has fertility, sperm donation or egg donation plans during the trial period; the female subject is pregnant, lactating or having a positive pregnancy test.
- •The subject is legally disabled by reference to the law of the people's Republic of China on the protection of disabled persons (April 2008).
- •The subject has any other unsuitable condition (such as factors reducing the follow-up compliance) to be determined by the investigator.
- •The Kellgren Lawrence grade (X-ray axial position of knee joint) of any knee joint of the subjects was grade IV.
研究组 & 干预措施
Mesenchymal progenitor cells
Experimental
Mesenchymal progenitor cells group
干预措施: Mesenchymal progenitor cells (Biological)
Sodium hyaluronate
Active Comparator
Sodium hyaluronate injection group
干预措施: Sodium Hyaluronate Injection (Drug)
结局指标
主要结局
WOMAC score
时间窗: 24 weeks
The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points；96 points mean a worse outcome,will be tested at 24 weeks after the first injection
次要结局
- WOMAC Score(4、12、24、36、48、60、72、84、96 weeks)
- MRI quantitative analysis of articular cartilage(24 weeks and 96 weeks)
- mJSW(96 weeks)
- Physical examination(Day 0、week 1、2、3、4、12、24、36、48、60、72、84、96)
- Whole-Organ Magnetic Resonance Imaging Score(24、48 and 96 weeks)
- Adverse Events and Serious Adverse Events(Day 0 to 96 weeks)
- VAS Score(4、12、24、36、48、60、72、84、96 weeks)
- SF-36(4、12、24、36、48、60、72、84、96 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
招募中
3 期
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee OsteoarthritisKnee OsteoarthritisNCT06570291Wuxi Cellular Biopharmaceutical Group Ltd.520
已完成
2 期
Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee OsteoarthritisKnee OsteoarthritisNCT04208646Shanghai AbelZeta Ltd.106
已完成
1 期
Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee OsteoarthritisOsteoarthritisNCT02641860Shanghai AbelZeta Ltd.22
Unknown
2 期
Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic StrokeIschemic StrokeAdipose Tissue-derived Stem CellFunctional StatusNCT04280003Instituto de Investigación Hospital Universitario La Paz30
已完成
1 期
Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19Sars-CoV2NCT04366323Andalusian Network for Design and Translation of Advanced Therapies26